IDEXX Laboratories stock (US45168D1046): Recent earnings beat and analyst price target update

IDEXX Laboratories reported quarterly revenue of $1.14 billion, up 14.3% year-over-year and beating estimates. Analyst consensus price target adjusted to $714.36 amid ongoing pet diagnostics growth.

IDEXX Laboratories, a leader in veterinary diagnostics, recently posted strong quarterly results with revenue climbing 14.3% year-over-year to $1.14 billion, surpassing the consensus estimate of $1.12 billion, according to MarketBeat as of 2026. In the prior quarter, the company delivered $3.47 EPS, topping expectations of $3.41. These figures underscore robust demand in the pet health sector.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: IDEXX Laboratories
• Sector/industry: Healthcare / Veterinary Diagnostics
• Headquarters/country: United States
• Core markets: North America, Europe
• Key revenue drivers: Companion animal diagnostics, livestock testing
• Home exchange/listing venue: Nasdaq (IDXX)
• Trading currency: USD

IDEXX Laboratories: core business model

IDEXX Laboratories develops and distributes products for companion animal and livestock diagnostics, water testing, and dairy monitoring. The company operates through segments including Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Dairy. CAG, its largest unit, provides diagnostic instruments, consumables, and software for veterinary practices worldwide. This model benefits from recurring revenue via consumables for in-house analyzers.

Headquartered in Westbrook, Maine, IDEXX serves over 175 countries, with a strong US presence where pet ownership drives demand. The firm's innovation in point-of-care testing positions it as a key player for US veterinarians seeking rapid diagnostics.

Main revenue and product drivers for IDEXX Laboratories

Companion animal diagnostics account for the bulk of revenue, fueled by premium instruments like Catalyst One and ProCyte Dx chemistry analyzers. Reference lab services and SNAP rapid tests further bolster CAG growth. In recent quarters, quarterly revenue reached $1.14 billion for the period ending in early 2026, up 14.3% from the prior year, as reported by MarketBeat as of 2026.

Livestock and water quality products provide diversification, with US agricultural exposure adding relevance for American investors tracking agribusiness trends. Over the last four quarters through early 2026, IDEXX generated $13.58 EPS, reflecting consistent profitability.

Industry trends and competitive position

The veterinary diagnostics market is expanding due to rising pet humanization and preventive care in the US, where 70% of households own pets. IDEXX holds a dominant share in chemistry and hematology analyzers, outpacing rivals through integrated ecosystems of hardware and software. Sector growth is projected at double digits annually, per industry reports.

Why IDEXX Laboratories matters for US investors

Listed on Nasdaq, IDEXX offers US investors exposure to the resilient pet economy, less correlated with broader market cycles. With significant North American revenue—over 50% from the US—the stock reflects domestic trends in veterinary spending, which hit record highs post-pandemic. Its Nasdaq listing ensures liquidity for retail portfolios.

Conclusion

IDEXX Laboratories continues to demonstrate strength in veterinary diagnostics, with recent earnings beats and a stable analyst outlook signaling operational momentum. While pet health trends support growth, the company navigates competitive pressures and economic sensitivities in animal care spending. Investors monitoring Nasdaq-listed healthcare names will find its US-centric revenue profile noteworthy.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.